TB

Tolerance Bio


Company Overview



Tolerance Bio is a Philadelphia-based biopharmaceutical company dedicated to the development of therapies designed to preserve, restore, and manipulate thymus function, which serves as the master regulator of immune tolerance. The company's focus is to increase healthspan by targeting immune-mediated diseases using advanced thymus-based therapies. Recently, Tolerance Bio launched successfully with support from a $17.2 million seed financing round.

Leadership Team



  • Francisco Leon, M.D., Ph.D.: Founder and CEO, previously co-founded Provention Bio, sold for $2.9 billion. An immunologist pioneering immune tolerance strategies.

  • Holger Russ, Ph.D.: Co-founder, pivotal scientific lead, with a focus on the immune-tissue interface vital for developing therapeutic strategies.

  • Justin Vogel: Chief Financial Officer with nearly twenty years in biotech finance leadership, steering financial strategy and capital acquisitions.

  • Phil Ball, Ph.D.: Senior Vice President, possesses extensive international biopharmaceutical experience, focused on drug development.

  • Yeh-Chuin Poh, Ph.D.: Vice President of Technical Operations, overseeing cell and gene therapy processes, with previous senior roles at Vertex Pharmaceuticals.

  • Paul Dunford: Vice President of Translational Science, with over 25 years in pharmaceutical R&D, enhancing immunological therapeutic development.

  • Christian Blount, MBA, PMP: Senior Director of Program Management, specializing in project management within biologics and cell and gene therapy domains.


Recent Achievements



Successful capital acquisition of $17.2 million in seed financing, demonstrating investor confidence in Tolerance Bio’s innovative platforms aimed at thymus-mediated immune health.

Strategic Vision



Tolerance Bio aims to be a leader in immune tolerance therapies, targeting revolutionary treatments for autoimmune diseases. With strong leadership, robust financing, and a clear scientific direction, the company seeks significant biopharmaceutical industry contributions.

Competitor Analysis



ArriVent BioPharma



  • Founded: 2021, USA

  • Focus: Oncology, with a Phase III trial for non-small cell lung cancer.

  • Funding: $155 million Series B, backed by global investors.



BioNeex, Inc.



  • Founded: 2021, USA

  • Focus: AI-powered R&D platform, facilitating biotech partnerships.



Antagen Pharmaceuticals, Inc.



  • Founded: 2008, USA

  • Focus: Glyco-engineered antibodies and immuno-oncology assay services.



Nona Biosciences



  • Founded: 2022, USA

  • Focus: Comprehensive biotherapeutic solutions focusing on antibody discovery.



Montara Therapeutics, Inc.



  • Founded: 2023, USA

  • Focus: Precision medicine for neurological diseases using the BrainOnly™ platform.

  • Funding: $8 million seed round.